The approval in the second-line EGFR- and MET-altered setting was based on results from the SACHI trial, which compared Orpathys and Tagrisso against chemo.

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the New Drug Application (“NDA”) ...

An AI system called iSeg is reshaping radiation oncology by automatically outlining lung tumors in 3D as they shift with each ...

When non-small cell lung cancer (NSCLC) spreads beyond the lungs, it often metastasizes to the bones. Estimates suggest 20 to 30 percent of people with NSCLC have bone metastases at the time of ...

The collaboration aims to evaluate the combination across three priority tumor types, including RAS mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer.

Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic ...

DNMT3A mutations emerged as potential biomarkers for enhanced immunotherapy benefit in non-small cell lung cancer.

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving ...